Barragan EV, Anisimova M, Vijayakumar V, Coblentz A, Park DK, Salaka RJ, Nisan AFK, Petshow S, Dore K, Zito K, and Gray JA (2024). D-serine inhibits non-ionotropic NMDA receptor signaling, Journal of Neuroscience, 44(32): e0140242024. PDF
Folorunso OO, Brown SE, Baruah J, Harvey TL, Jami SA, Radzishevsky I, Wolosker H, McNally JM, Gray JA, Vasudevan A, and Balu DT (2023). D-serine availability modulates prefrontal cortex inhibitory interneuron development and circuit maturation, Scientific Reports, 13: 9595.
PDF
Gonzalez-Gonzalez IM, Gray JA, Ferreira J, Conde-Dusman MJ, Bouchet D, Perez-Otano I, and Groc L (2023). GluN3A subunit tunes NMDA receptor synaptic trafficking and content during postnatal brain development, Cell Reports, 42(5): 112477. PDF
Vargas MV, Dunlap LE, Dong C, Carter SJ, Tombari RJ, Jami SA, Cameron LP, Patel SD, Hennessey J, Saeger HN, McCorvy JD, Gray JA, Tian L, and Olson DE (2023). Psychedelics promote neuroplasticity through activation of intracellular 5-HT2A receptors, Science, 379(6633): 700-706. PDF
Cameron LP, Patel SD, Vargas MV, Barragan EV, Saeger HN, Warren HT, Chow WL, Gray JA, and Olson DE (2023). 5-HT2ARs mediate therapeutic behavioral effects of psychedelic tryptamines, ACS Chemical Neuroscience, 14(3): 351-358. PDF
Wang Y, Zhang S, Lan Z, Doan V, Kim B, Liu S, Zhu M, Hull V, Rihani S, Zhang CL, Gray JA, and Guo F (2022). SOX2 is essential for astrocyte maturation and its deletion leads to hyperactive behavior in mice, Cell Reports, 41(12): 111842. PDF
Park DK, Petshow SJ, Anisimova M, Barragan EV, Gray JA, Stein IS, and Zito K (2022). Reduced D-serine levels drive enhanced non-ionotropic NMDA receptor signaling and destabilization of dendritic spines in a mouse model for studying schizophrenia, Neurobiology of Disease, 170: 105772. PDF
Berg EL, Jami SA, Petkova SP, Berz A, Fenton TA, Lerch JP, Segal DJ, Gray JA, Ellegood J, Wohr M, and Silverman JL (2021). Excessive laughter-like vocalizations, microcephaly, and translational outcomes in the Ube3a deletion rat model of Angelman Syndrome. Journal of Neuroscience, 41(42): 8801-8814. PDF
Jami SA, Cameron S, Wong JM, Daly ER, McAllister AK, and Gray JA (2021). Increased excitation-inhibition balance and loss of GABAergic synapses in the serine racemase knockout model of NMDA receptor hypofunction. Journal of Neurophysiology, 126(1): 11-27. PDF
Wong JM, Folorunso OO, Barragan EV, Berciu C, Harvey TL, Coyle JT, Balu DT, and Gray JA (2020). Postsynaptic serine racemase regulates NMDA receptor function. Journal of Neuroscience, 40(50): 9564-9575. PDF
Li W, Kutas M, Gray JA, Hagerman R, and Olichney J (2020). The role of glutamate in language and language disorders: evidence from ERP and pharmacological studies, Neuroscience and Biobehavioral Reviews, 119: 217-241. PDF
Chiu AM, Wang J, Fiske MP, Hubalkova P, Barse L, Gray JA, and Sanz-Clemente A (2019). NMDAR-activated PP1 dephosphorylates GluN2B to modulate NMDAR plasticity. Cell Reports, 28(2): 332-341. PDF
Crestani AP, Krueger JN, Barragan EV, Nakazawa Y, Nemes SE, Quillfeldt JA, Gray JA, and Wiltgen BJ (2019). Metaplasticity contributes to memory formation in the hippocampus. Neuropsychopharmacology, 44(2): 408-412. PDF
Yang XY, Stanley RE, Ross AP, Robitaille AM, Gray JA, and Cheyette BNR (2019). Sestd1 encodes a developmentally dynamic synapse protein that complexes with BCR Rac1-GAP to regulate forebrain dendrite, spine and synapse formation. Cerebral Cortex, 29(2): 505-516. PDF
Minnella AM, Zhao JX, Jiang X, Jakobsen E, Lu F, Wu L, El-Benna J, Gray JA, and Swanson RA (2018). Excitotoxic superoxide production and neuronal death require both ionotropic and non-ionotropic NMDA receptor signaling, Scientific Reports, 8: 17522. PDF
Sun W, Wong JM, Gray JA*, and Carter BC* (2018). Incomplete block of NMDA receptors by intracellular MK-801. Neuropharmacology, 143: 122-129. (*co-corresponding authors) PDF
Wong JM and Gray JA (2018). Long-term depression is independent of GluN2 subunit composition. Journal of Neuroscience, 38(19): 4462-4470. PDF
Ly C, Greb AC, Cameron LP, Wong JM, Barragan EV, Wilson P, Burbach KF, Dunlap LE, Zarandi SS, Sood A, Paddy MR, Duim WC, Dennis MY, McAllister AK, Ori-McKenney KM, Gray JA, and Olson DE (2018). Psychedelics Promote Structural and Functional Neural Plasticity. Cell Reports, 23(11): 3170-3182. PDF
Gray JA, Zito K, and Hell JW (2016). Non-ionotropic signaling by the NMDA receptor: controversy and opportunity. F1000 Research, 5(F1000 Faculty Rev): 1010. PDF
Stein IS, Gray JA, and Zito K (2015). Non-ionotropic NMDA receptor signaling drives activity-induced dendritic spine shrinkage. Journal of Neuroscience, 35(35): 12303-12308. PDF
Sanz-Clemente A, Gray JA, Nicoll RA, and Roche KW (2013). Activated CaMKII couples GluN2B and Casein Kinase 2 to control synaptic NMDA receptors. Cell Reports, 3(3): 607-614. PDF
Gray JA and Nicoll RA (2012). Thinking outside the synapse: glycine at extrasynaptic NMDA receptors. Cell, 150(3): 455-456. PDF
Chen BS*, Gray JA*, Sanz-Clemente A, Wei Z, Thomas EV, Nicoll RA, and Roche KW (2012). SAP102 mediates synaptic clearance of NMDA receptors. Cell Reports, 2(5): 1120-1128. (*co-first authors) PDF
Gray JA (2012). Parkinsonism and rabbit syndrome following discontinuation of low-dose ziprasidone and concomitant initiation of sertraline. Journal of Clinical Psychopharmacology, 32(1): 142-143. PDF
Gray JA, Shi Y, Usui H, During MJ, Sakimura K, Nicoll RA (2011). Distinct modes of AMPA receptor suppression at developing synapses by GluN2A and GluN2B: single-cell NMDA receptor subunit deletion in vivo. Neuron, 71(6): 1085-1101. PDF
Granger AJ, Gray JA, Lu W, and Nicoll RA (2011). Genetic analysis of neuronal ionotropic glutamate receptor subunits. Journal of Physiology, 589(17): 4095-4101. PDF
Lu W*, Gray JA*, Granger AJ, During MJ, Nicoll RA (2011). The potentiation of synaptic AMPA receptors induced by the deletion of NMDA receptors requires the GluA2 subunit. Journal of Neurophysiology, 105(2): 923-928. (*co-first authors) PDF
Juge N, Gray JA, Omote H, Miyaji T, Inoue T, Hara C, Uneyama H, Edwards RH, Nicoll RA, Moriyama Y (2010). Metabolic control of vesicular glutamate transport and release. Neuron, 68(1): 99-112. PDF
Gray JA and Risch SC (2009). When clozapine is not enough. Augment with lamotrigine? Current Psychiatry, 8(1): 41-46. PDF
Berger M, Gray JA, and Roth BL (2009). The expanded biology of serotonin. Annual Review of Medicine, 60: 355-366. PDF
Gray JA and Roth BL (2007). The pipeline and future of drug development in schizophrenia. Molecular Psychiatry, 12(10): 904-922. PDF
Gray JA and Roth BL (2007). Molecular targets for treating cognitive dysfunction in schizophrenia. Schizophrenia Bulletin, 33(5): 1100-1119. PDF
Gray JA and Roth BL (2006). Developing selectively non-selective drugs for treating CNS disorders. Drug Discovery Today: Therapeutic Strategies, 3(4): 413-419. PDF
Xia Z, Hufeisen SJ, Gray JA, and Roth BL (2003). The PDZ-binding domain is essential for the dendritic targeting of 5-HT2A serotonin receptors in cortical pyramidal neurons in vitro. Neuroscience, 122(4): 907-920. PDF
Gray JA, Compton-Toth BA, and Roth BL (2003). Identification of two serine residues essential for agonist-induced 5-HT2A receptor desensitization. Biochemistry, 42(36): 10853-10862. PDF
Xia Z, Gray JA, Compton-Toth BA, and Roth BL (2003). A direct interaction of PSD-95 with 5-HT2A serotonin receptors regulates receptor trafficking and signal transduction. Journal of Biological Chemistry 278(24): 21901-21908. PDF
Gray JA, Bhatnagar A, Gurevich VV, and Roth BL (2003). The interaction of a constitutively active arrestin with the arrestin-insensitive 5-HT2A receptor induces agonist-independent internalization. Molecular Pharmacology 63(5): 961-972. PDF
Gray JA and Roth BL (2002). A Last GASP for GPCRs? Science 297: 529-531. PDF
Gray JA, Sheffler DJ, Bhatnagar A, Woods JA, Hufeisen SJ, Benovic JL, and Roth BL (2001). Cell-type specific effects of endocytosis inhibitors on 5-HT2A receptor desensitization and resensitization reveal an arrestin-, GRK2- and GRK5-independent mode of regulation in HEK-293 cells. Molecular Pharmacology 60(5): 1020-1030. PDF
Gray JA and Roth BL (2001). Paradoxical trafficking and regulation of 5-HT2A receptors by agonists and antagonists. Brain Research Bulletin 56(5): 441-451. PDF
Bhatnagar A, Willins DL, Gray JA, Woods JA, Benovic JL, and Roth BL (2001). The dynamin-dependent, arrestin-independent internalization of 5-hydroxytryptamine2A (5-HT2A) serotonin receptors reveals differential sorting of arrestins and 5-HT2A receptors during endocytosis. Journal of Biological Chemistry 276(11): 8269-8277. PDF
Gelber EI, Kroeze WK, Willins DL, Gray JA, Sinar CA, Hyde EG, Gurevich V, Benovic JL, and Roth BL (1999). Structure and function of the third intracellular loop of the 5-hydroxytryptamine2A receptor: the third intracellular loop is alpha-helical and binds purified arrestins. Journal of Neurochemistry 72: 2206-2214. PDF
Book Chapters
Gray JA (2024). Intraneuronal Signaling, in Kaplan & Sadock’s Comprehensive Textbook of Psychiatry – Eleventh Edition. Sadock BJ, Sadock VA and Ruiz P (Eds.) Lippincott Williams & Wilkins, Philadelphia, PA, in press.
Gray JA (2024). Introduction to the Pharmacology of CNS Drugs, in Katzung’s Basic and Clinical Pharmacology 16E. Vanderah TW (Ed.), McGraw-Hill, New York, NY, pp 385-398.
Paudel S and Gray JA (2021). Tardive Dyskinesia, in Ferri’s Clinical Advisor 2022. Ferri FF (Ed.), Mosbi, Philadelphia, PA, p 1463.
Gray JA (2020). Introduction to the Pharmacology of CNS Drugs, in Basic and Clinical Pharmacology 15E. Katzung BG (Ed.), McGraw-Hill, New York, NY, pp 381-394.
Gray JA (2020). Tardive Dyskinesia, in Ferri’s Clinical Advisor 2021. Ferri FF (Ed.), Mosbi, Philadelphia, PA, p 1342.
Gray JA (2019). Tardive Dyskinesia, in Ferri’s Clinical Advisor 2020. Ferri FF (Ed.), Mosbi, Philadelphia, PA, p 1347.
Gray JA (2018). Tardive Dyskinesia, in Ferri’s Clinical Advisor 2019. Ferri FF (Ed.), Mosbi, Philadelphia, PA, p 1346.
Gray JA (2017). Introduction to the Pharmacology of CNS Drugs, in Basic and Clinical Pharmacology 14E. Katzung BG (Ed.), McGraw-Hill, New York, NY, pp 367-380.
Gray JA and Roth BL (2017). Intraneuronal Signaling, in Kaplan & Sadock’s Comprehensive Textbook of Psychiatry – Tenth Edition. Sadock BJ, Sadock VA and Ruiz P (Eds.) Lippincott Williams & Wilkins, Philadelphia, PA, pp 119-130.
Gray JA (2017). Tardive Dyskinesia, in Ferri’s Clinical Advisor 2018. Ferri FF (Ed.), Mosbi, Philadelphia, PA, p 1251.
Gray JA (2016). Tardive Dyskinesia, in Ferri’s Clinical Advisor 2017. Ferri FF (Ed.), Mosbi, Philadelphia, PA, p 1247.
Gray JA (2015). Tardive Dyskinesia, in Ferri’s Clinical Advisor 2016. Ferri FF (Ed.), Mosbi, Philadelphia, PA, p 1198.
Gray JA and Nicoll RA (2014). Introduction to the Pharmacology of CNS Drugs, in Basic and Clinical Pharmacology 13E. Katzung BG (Ed.), McGraw-Hill, New York, NY, pp 355-368.
Gray JA (2014). Tardive Dyskinesia, in Ferri’s Clinical Advisor 2015. Ferri FF (Ed.), Mosbi, Philadelphia, PA, p 1148.
Gray JA (2013). Tardive Dyskinesia, in Ferri’s Clinical Advisor 2014. Ferri FF (Ed.), Mosbi, Philadelphia, PA, p 1078.
Gray JA (2012). Tardive Dyskinesia, in Ferri’s Clinical Advisor 2013. Ferri FF (Ed.), Mosbi, Philadelphia, PA, p 1067.
Gray JA (2011). Tardive Dyskinesia, in Ferri’s Clinical Advisor 2012. Ferri FF (Ed.), Mosbi, Philadelphia, PA, p 997.
Gray JA (2010). Tardive Dyskinesia, in Ferri’s Clinical Advisor 2011. Ferri FF (Ed.), Mosbi, Philadelphia, PA, pp 1069-1070.
Gray JA and Roth BL (2009). Intraneuronal Signaling, in Kaplan & Sadock’s Comprehensive Textbook of Psychiatry – Ninth Edition. Sadock BJ, Sadock VA and Ruiz P (Eds.) Lippincott Williams & Wilkins, Philadelphia, PA, pp 118-129.
Gray JA and Lai A (2009). Tardive Dyskinesia, in Ferri’s Clinical Advisor 2010. Ferri FF (Ed.), Mosbi, Philadelphia, PA, p 976.
Gray JA and Roth BL (2007). Serotonin Systems, in Handbook of Contemporary Neuropharmacology. Sibley DR, Hanin I, Kuhar M and Skolnick P (Eds.), John Wiley & Sons, New York, NY, pp 257-298.